Historic Day for Pfizer (PFE), Covid-19 Vaccine

Mark Vickery
·3 min read

Monday, December 14, 2020

Pfizer PFE
and BioNTech’s BNTX Covid-19 vaccine has now made it to U.S. shores. It’s an historic development to counter the worst pandemic in over 100 years. With an OK from the U.S. Food & Drug Administration (FDA), distribution of the vaccine begins. That it comes at near-peak Covid-19 spread — more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone — makes this vaccine availability not just historic, it’s momentous.

Market indexes are up as a result, and not just Pfizer’s 1% gain thus far in the pre-market. Looks at Restaurant Brands QSR, which is up 2% in early Monday trading: bringing the American — and global — economy back to pre-pandemic levels will be especially pronounced in companies that have been hit by a wet blanket since the first Covid-related death on U.S. soil roughly 10 months ago. We saw this with oil & gas names when positive news in phase-3 trials came out; ConocoPhillips COP is up 52% from October 30th, for instance.

For $60 per share in cash and 2+ in American Depositary Shares (ADS), AstraZeneca AZN has agreed to purchase rare-disease treatment manufacturer Alexion ALXN. The total sum of the agreement comes to $39 billion, which some market participants may feel is a bit steep: AstraZeneca shares are down 7% in early-morning trading. The blockbuster drug from Alexion is called Soliris, which treats a spectrum of rare diseases, and the company stock is up 30% this morning on the news.

Alexion had previously been considered an acquisition target, but ran into some entanglements that took some changes in the front office to correct. As far as AstraZeneca, it had been in the running for a first-to-market Covid-19 vaccine, but some irregularities in its phase-3 testing caused many to push pause. Its candidate, developed in tandem with Oxford University, follows a more historic path to immunization than the mRNA vaccines of Pfizer and Moderna MRNA.

We won’t see any major economic reports hitting the tape this morning, but this changes significantly as the week moves along: Import Prices, the Empire State index, Industrial Production/Capacity Utilization,  Retail Sales, Housing Starts/Building Permits, and, of course, Weekly Jobless Claims are all on deck a week before Christmas, as well as the fifth day of Hanukkah. Until then, markets are performing well after taking a breather last week; the Covid-19 vaccinations in the U.S. will remain the big story throughout the day.

Questions or comments about this article and/or its author? Click here>>

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
ConocoPhillips (COP) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
Restaurant Brands International Inc. (QSR) : Free Stock Analysis Report
 
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research
 
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report